Our experts Globally known clinical researchers, wound healing experts, dedicated & passionate
Since its science & technology discovering, Remedor experts bring a relentless drive for innovation and a passion for delivering a novel wound treatment modality. They joined Remedor because they are fascinated with our innovation: "we can literally save millions of lives and improve the quality of life of millions of patients with chronic wounds and their families".
We understand that besides our novel technology and breakthrough products, trust, dedication and experience are also essential to be a reliable innovator to the pharmaceutical industry. Remedor team has the most known clinical researchers and industry experts of the wound healing field in order to introduce our novel technology to fulfill the specific requirements of our patients and their wound care providers.
We invite you to discover what our experts say about our novel technology:
Professor of Plastic & Reconstructive Surgery and Chair of Remedor's Medical Research & Advisory Board.
Professor Luc Teot is the Founding President of the French Society of Wound Care. He was the President of the World Union of Wound Healing Societies (WUWHS) and the President of the European Tissue Repair Society (ETRS). Besides his position in Remedor, Professor Luc Teot serves also as a Member of the Biomedical Advisory Board of LifeWave Ltd. Professor Luc Teot serves on a numerous potential journal editorial boards of the wound healing field including the journal of Wound Repair & Regeneration and the journal of Advanced Wound Care. He is the author of significant international publications in the leading peer-reviewed journals such as The Lancet, Plast & Rec Surg, Annals of Plast Surg and British J Plast Surg, He has authored eight books and written 17 chapters about wound healing. Professor Luc Teot is qualified in General, Orthopedic & Plastic Surgery and is an expert in diabetic foot ulcer and burn healing.
Professor Luc Teot talking about Remedor's breakthrough technology
"I'm thrilled to be part of Remedor's innovation for wound healing. Development of innovative pharmaceuticals at this time is a key element for patients suffering of chronic wounds such diabetic patients with non-healing foot ulcers. I work with Remedoron the development of its exciting novel technology which is highly safe and able to stimulate significantly quick wound healing, thus reducing the risks for infection, bad scar or recurrences. The leading product of Remedor, WondaGel has a specific mechanism of action. WondaGel boosts the skin cell reactions thus activating the cascades issuing to complete closure. Based on experimental data and clinical trials published in high level peer-reviewed journals, we provide a solid evidence that Remedor's technology will be able to occupy the wound healing industry. However, we are enthusiast to achieve our advanced clinical trials and regulatory requirements to introduce Remedor's products into the wound healing market. In Remedor, we work together with an international panel of colleagues devoted to Remedor's technology clinical research to bring its innovative solutions into the hands of patients as soon as possible."
Professor of Plastic & Reconstructive Surgery and Dermeos' Vice President Clinical Research.
Professor Sadanori Akita did his residency in plastic surgery at Nagasaki University Hospital. He received his PhD from the Graduate School of Nagasaki University specializing in plastic and reconstructive surgery. He later did a research fellowship at Cedars-Sinai Medical Center, University of California, Los Angeles (UCLA). Professor Sadanori Akita served as President of the World Union of Wound Healing Societies (WUWHS) from 2012- 2016. He is also currently President of the Asian Wound Care Association (AWCA). His research interests include: cytokines and stem cells in wound healing, difficult wound healing (radiation injury), regenerative tissue enhancement to HIV-drug related-wasting patients, reconstructive surgery, burn and craniofacial surgery. Professor Akita’s publications include over than 65 peer-reviewed original articles, 12 overviews, and 14 book chapters with 3 editorship of the books in the field of wound healing.
Professor Sadanori Akita talking about Remedor's novel technology
"The leading product of Remedor's novel technology "WondaGel" may play a pivotal role in the disabling and life-threatening diabetic foot ulcer (DFU) problem, which otherwise often result in major amputation. Conventional modalities of endovascular or distal bypass surgery may bring about better vasculature in local tissue but WondaGel would improve even much tiny tissue perfusion via a very novel pathway, which is scientifically has been proven in both animal studies and clinically. Because of its nature Remedor's technology even extend to clinical effect event to congenital skin diseases such as "Epidermplysis Bullosa", which demonstrates very brittle skin barrier and loss of integrity and thus leading to high rate of skin infection or severe dehydration due to loss of skin barrier function. With the Remedor's orphan drug "RevidraGel", such a severe skin condition can be safely and effectively treated with no major modality or comorbidity. RevidraGel will definitely be the choice of wound healing, especially hard-to-heal wounds."
Professor of Plastic Surgery at The Warren Alpert Medical School of Brown University and Member of the Remedor's Medical Advisory Board.
Professor Paul Liu is Chairman of the Department of Plastic Surgery for the Lifespan Hospital System in Rhode Island, USA, and Professor of Surgery at the Alpert Medical School of Brown University. He received his medical education at Harvard Medical School and did residencies in general and plastic surgery at the Brigham and Women’s Hospital and Children’s Hospital in Boston, Massachusetts. He received a Marshall Scholarship for graduate study at Oxford University, where he received an Honors MA. He has been President of the Wound Healing Society and currently serves as Secretary for the Wound Healing Foundation. His research interests include diabetic wound healing, gene therapy applications in wound healing, mathematical modeling of wound healing, and histone acetylation-mediated mechanisms of stem cell plasticity in ischemia reperfusion injury.
Professor Paul Liu talking about Remedor's game-changer technology
"Remedor's topical pharmaceutical technology is showing promise in the healing of human wounds under challenging circumstances. We have seen its’ positive effect in the preclinical models of diabetic mice, rats, and pigs, where it accelerated wound closure over control treatments. More recently, Remedor's WoundaGel performed well in advanced clinical trials. WoundaGel has accelerated healing of complex ulcers in diabetic patients. In the U.S., there is currently a dearth of pharmacologic agents to assist wound healing, so this is a welcome development. In particular, our work has shown that the positive effects of WoundaGel is binificial due to the lack of significant toxicities and a broad therapeutic window may enhance it’s utility. Undoubtedly, Remedor's technology would be a game-changer in the field of wound healing. Since Remedor establishment we work together effortlessly to bring this exciting safe and effective novel therapy into market. Either topical WondaGel, ReviraGel and B-Gel may change the lives of many patients with complex wounds to better. Remedor's topical products can address wide wound problems such as the deblitating diabetic foot ulcer condition, wounds of the epidermolysis bullosa rare disease and burns. Because of the safety nature of Remedor's products and their power to accelerate wound healing, they will be all the preferred products to the wound care providers."
Doctor Kirehuel is the President of Vertical S.A.R.L and the Manager of Remedor's Clinical Research & Trials.
Doctor Kerihuel has M.D. He has Post-graduated in toxicology (1979) and in clinical pharmacology and biomathematics (1983) from Paris V Univerity. Doctor Kerihuel served as Manager of Clinical Research Division (Bayer France and Germany), Manager of Pharmacological and Clinical Research (AKZO France and The Netherlands). Manager of Pharmacological and Clinical Research (E. Merck Germany), and worked as Consultant for the pharmaceutical industry since 1991. Doctor Keriheul is the Founder and General Manager of Vertical S.A.R.L, a consulting company aiming to scientifically support health industry in research and development projects. For more than 15 years 60% of Vertical activities are dedicated to medical devices and wound healing technologies. Doctor Kerihuel is also a Lecturer in different University Post-graduation Courses in clinical pharmacology and regulatory matters since 1988 at the University of Paris VI, and a Lecturer in in different University Post-graduation Courses in vascular diseases and tissue repair pharmacology.
Doctor Kerihuel talking about Remedor's clinical trials:
"Topical EPO (WondaGel) may play pivotal role in intractable chronic diabetic foot ulcers, DFUs, which otherwise often result in major amputation. Conventional modalities of endovascular or distal bypass surgery may bring about better vasculature in local tissue but WondaGel wound improve even much tiny tissue perfusion via very novel pathway, which is proved both in scientifically and clinically. Because of its nature EPO product such as WondaGel even extend to clinical effect event to congenital skin disease such as Epidermplysis Bullosa, which demonstrates very brittle skin barrier and loss of integrity and thus leading to high rate of skin infection or severe dehydration due to loss of skin barrier function. With WondaGel, such severe skin condition can be safely and effectively treated with no major modality or comorbidity. WondaGel will definitely be the choice of wound healing, especially hard-to-heal wounds.